| 1 |
34863048 | Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase. | 2022 May |
1 |
| 2 |
34951129 | A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114. | 2022 May |
1 |
| 3 |
35397172 | Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. | 2022 Jul |
2 |
| 4 |
33544210 | Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. | 2021 May |
2 |
| 5 |
33755421 | The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil. | 2021 Apr 13 |
2 |
| 6 |
33895696 | Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. | 2021 Jun |
1 |
| 7 |
34032117 | Perturbing the Movement of Hydrogens to Delineate and Assign Events in the Reductive Activation and Turnover of Porcine Dihydropyrimidine Dehydrogenase. | 2021 Jun 8 |
2 |
| 8 |
34442436 | DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. | 2021 Aug 13 |
1 |
| 9 |
34717904 | Mammalian dihydropyrimidine dehydrogenase. | 2021 Dec 15 |
2 |
| 10 |
32058656 | A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer. | 2020 Jul |
1 |
| 11 |
32088324 | An improved method for the expression and purification of porcine dihydropyrimidine dehydrogenase. | 2020 Jul |
2 |
| 12 |
32516529 | Transient-State Analysis of Porcine Dihydropyrimidine Dehydrogenase Reveals Reductive Activation by NADPH. | 2020 Jul 7 |
2 |
| 13 |
32595208 | A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. | 2020 Sep |
1 |
| 14 |
32649488 | 5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation. | 2020 Oct |
2 |
| 15 |
32899374 | A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. | 2020 Sep 3 |
1 |
| 16 |
30807536 | Determination of Endogenous Concentrations of Uracil and Dihydrouracil in Dried Saliva Spots by LC-MS/MS: Method Development, Validation, and Clinical Application. | 2019 Jun |
2 |
| 17 |
31486738 | Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. | 2019 Aug |
2 |
| 18 |
29430582 | The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. | 2018 Jun |
1 |
| 19 |
29769267 | Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals. | 2018 Aug |
1 |
| 20 |
28427087 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. | 2017 May 23 |
1 |
| 21 |
28481884 | New advances in DPYD genotype and risk of severe toxicity under capecitabine. | 2017 |
1 |
| 22 |
28501750 | Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma. | 2017 Aug 5 |
2 |
| 23 |
29372689 | DPYD genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from Slovakia. | 2017 Dec |
1 |
| 24 |
26265035 | Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. | 2016 Feb |
2 |
| 25 |
26551538 | Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. | 2016 Mar |
1 |
| 26 |
26804652 | Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. | 2016 Apr |
5 |
| 27 |
27179185 | Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. | 2016 Jul 15 |
2 |
| 28 |
25940841 | Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase. | 2015 Sep |
2 |
| 29 |
25957957 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. | 2015 Jul |
2 |
| 30 |
24401318 | microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. | 2014 Mar |
3 |
| 31 |
24452393 | First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. | 2014 Mar |
1 |
| 32 |
24648345 | Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. | 2014 May 1 |
2 |
| 33 |
25102934 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. | 2014 Oct |
5 |
| 34 |
25410891 | Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. | 2014 Sep |
2 |
| 35 |
22454320 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. | 2013 Jan |
1 |
| 36 |
22020693 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. | 2012 Jun 1 |
2 |
| 37 |
21590448 | Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. | 2011 Dec |
6 |
| 38 |
19381049 | [Significance of urinary uracil measurement following administration of DPD inhibitory fluoropyrimidine(DIF)products]. | 2009 Apr |
2 |
| 39 |
17637782 | Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. | 2008 Mar |
1 |
| 40 |
18172246 | Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? | 2008 Jan 1 |
2 |
| 41 |
18633222 | [Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer]. | 2008 Jun |
2 |
| 42 |
16556484 | FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD). | 2007 Feb 8 |
3 |
| 43 |
17143493 | Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. | 2007 Jan |
1 |
| 44 |
17308379 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. | 2007 |
2 |
| 45 |
17582309 | [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]. | 2007 Mar-Apr |
1 |
| 46 |
17603216 | Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. | 2007 Jun |
2 |
| 47 |
17952005 | Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. | 2007 |
2 |
| 48 |
16912518 | [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. | 2006 Aug |
2 |
| 49 |
17065072 | A pivotal role for beta-aminoisobutyric acid and oxidative stress in dihydropyrimidine dehydrogenase deficiency? | 2006 |
2 |
| 50 |
15899693 | Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. | 2005 Apr |
2 |